Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies

Goran Šimić*, Mirjana Babić Leko, Selina Wray, Charles Harrington, Ivana Delalle, Nataša Jovanov-Milošević, Danira Bažadona, Luc Buée, Rohan de Silva, Giuseppe Di Giovanni, Claude Wischik, Patrick R. Hof

*Corresponding author for this work

Research output: Contribution to journalReview article

133 Citations (Scopus)
8 Downloads (Pure)

Abstract

Abnormal deposition of misprocessed and aggregated proteins is a common final pathway of most neurodegenerative diseases, including Alzheimer’s disease (AD). AD is characterized by the extraneuronal deposition of the amyloid β (Aβ) protein in the form of plaques and the intraneuronal aggregation of the microtubule-associated protein tau in the form of filaments. Based on the biochemically diverse range of pathological tau proteins, a number of approaches have been proposed to develop new potential therapeutics. Here we discuss some of the most promising ones: inhibition of tau phosphorylation, proteolysis and aggregation, promotion of intra- and extracellular tau clearance, and stabilization of microtubules. We also emphasize the need to achieve a full understanding of the biological roles and post-translational modifications of normal tau, as well as the molecular events responsible for selective neuronal vulnerability to tau pathology and its propagation. It is concluded that answering key questions on the relationship between Aβ and tau pathology should lead to a better understanding of the nature of secondary tauopathies, especially AD, and open new therapeutic targets and strategies.

Original languageEnglish
Article number6
Number of pages27
JournalBiomolecules
Volume6
Issue number1
Early online date6 Jan 2016
DOIs
Publication statusPublished - Mar 2016

Fingerprint

Tauopathies
tau Proteins
Alzheimer Disease
Agglomeration
Pathology
Neurodegenerative diseases
Proteolysis
Enzyme inhibition
Serum Amyloid A Protein
Phosphorylation
Microtubule-Associated Proteins
Post Translational Protein Processing
Microtubules
Neurodegenerative Diseases
Stabilization
Therapeutics
Proteins

Keywords

  • Alzheimer’s disease
  • Amyloid β
  • Microtubules
  • Neurofibrillary degeneration
  • Neuropathology
  • Phosphorylation
  • Protein aggregation
  • Protein oligomerization
  • Tau protein
  • Tauopathies

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry
  • Molecular Biology

Cite this

Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies. / Šimić, Goran; Babić Leko, Mirjana; Wray, Selina; Harrington, Charles; Delalle, Ivana; Jovanov-Milošević, Nataša; Bažadona, Danira; Buée, Luc; de Silva, Rohan; Giovanni, Giuseppe Di; Wischik, Claude; Hof, Patrick R.

In: Biomolecules, Vol. 6, No. 1, 6, 03.2016.

Research output: Contribution to journalReview article

Šimić, G, Babić Leko, M, Wray, S, Harrington, C, Delalle, I, Jovanov-Milošević, N, Bažadona, D, Buée, L, de Silva, R, Giovanni, GD, Wischik, C & Hof, PR 2016, 'Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies', Biomolecules, vol. 6, no. 1, 6. https://doi.org/10.3390/biom6010006
Šimić, Goran ; Babić Leko, Mirjana ; Wray, Selina ; Harrington, Charles ; Delalle, Ivana ; Jovanov-Milošević, Nataša ; Bažadona, Danira ; Buée, Luc ; de Silva, Rohan ; Giovanni, Giuseppe Di ; Wischik, Claude ; Hof, Patrick R. / Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies. In: Biomolecules. 2016 ; Vol. 6, No. 1.
@article{aaafffddc7a047018e5d006e70669e26,
title = "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies",
abstract = "Abnormal deposition of misprocessed and aggregated proteins is a common final pathway of most neurodegenerative diseases, including Alzheimer’s disease (AD). AD is characterized by the extraneuronal deposition of the amyloid β (Aβ) protein in the form of plaques and the intraneuronal aggregation of the microtubule-associated protein tau in the form of filaments. Based on the biochemically diverse range of pathological tau proteins, a number of approaches have been proposed to develop new potential therapeutics. Here we discuss some of the most promising ones: inhibition of tau phosphorylation, proteolysis and aggregation, promotion of intra- and extracellular tau clearance, and stabilization of microtubules. We also emphasize the need to achieve a full understanding of the biological roles and post-translational modifications of normal tau, as well as the molecular events responsible for selective neuronal vulnerability to tau pathology and its propagation. It is concluded that answering key questions on the relationship between Aβ and tau pathology should lead to a better understanding of the nature of secondary tauopathies, especially AD, and open new therapeutic targets and strategies.",
keywords = "Alzheimer’s disease, Amyloid β, Microtubules, Neurofibrillary degeneration, Neuropathology, Phosphorylation, Protein aggregation, Protein oligomerization, Tau protein, Tauopathies",
author = "Goran Šimić and {Babić Leko}, Mirjana and Selina Wray and Charles Harrington and Ivana Delalle and Nataša Jovanov-Milošević and Danira Bažadona and Luc Bu{\'e}e and {de Silva}, Rohan and Giovanni, {Giuseppe Di} and Claude Wischik and Hof, {Patrick R.}",
note = "Acknowledgments This work was supported by The Croatian Science Foundation grant No. IP-2014-09-9730 (“Tau protein hyperphosphorylation, aggregation, and trans-synaptic transfer in Alzheimer’s disease: cerebrospinal fluid analysis and assessment of potential neuroprotective compounds”) and European Cooperation in Science and Technology (COST) Action CM1103 (“Stucture-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain”). PRH is supported in part by NIH grant P50 AG005138. We also thank Mate Babić for help in preparation of schematics.",
year = "2016",
month = "3",
doi = "10.3390/biom6010006",
language = "English",
volume = "6",
journal = "Biomolecules",
issn = "2218-273X",
publisher = "MDPI",
number = "1",

}

TY - JOUR

T1 - Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies

AU - Šimić, Goran

AU - Babić Leko, Mirjana

AU - Wray, Selina

AU - Harrington, Charles

AU - Delalle, Ivana

AU - Jovanov-Milošević, Nataša

AU - Bažadona, Danira

AU - Buée, Luc

AU - de Silva, Rohan

AU - Giovanni, Giuseppe Di

AU - Wischik, Claude

AU - Hof, Patrick R.

N1 - Acknowledgments This work was supported by The Croatian Science Foundation grant No. IP-2014-09-9730 (“Tau protein hyperphosphorylation, aggregation, and trans-synaptic transfer in Alzheimer’s disease: cerebrospinal fluid analysis and assessment of potential neuroprotective compounds”) and European Cooperation in Science and Technology (COST) Action CM1103 (“Stucture-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain”). PRH is supported in part by NIH grant P50 AG005138. We also thank Mate Babić for help in preparation of schematics.

PY - 2016/3

Y1 - 2016/3

N2 - Abnormal deposition of misprocessed and aggregated proteins is a common final pathway of most neurodegenerative diseases, including Alzheimer’s disease (AD). AD is characterized by the extraneuronal deposition of the amyloid β (Aβ) protein in the form of plaques and the intraneuronal aggregation of the microtubule-associated protein tau in the form of filaments. Based on the biochemically diverse range of pathological tau proteins, a number of approaches have been proposed to develop new potential therapeutics. Here we discuss some of the most promising ones: inhibition of tau phosphorylation, proteolysis and aggregation, promotion of intra- and extracellular tau clearance, and stabilization of microtubules. We also emphasize the need to achieve a full understanding of the biological roles and post-translational modifications of normal tau, as well as the molecular events responsible for selective neuronal vulnerability to tau pathology and its propagation. It is concluded that answering key questions on the relationship between Aβ and tau pathology should lead to a better understanding of the nature of secondary tauopathies, especially AD, and open new therapeutic targets and strategies.

AB - Abnormal deposition of misprocessed and aggregated proteins is a common final pathway of most neurodegenerative diseases, including Alzheimer’s disease (AD). AD is characterized by the extraneuronal deposition of the amyloid β (Aβ) protein in the form of plaques and the intraneuronal aggregation of the microtubule-associated protein tau in the form of filaments. Based on the biochemically diverse range of pathological tau proteins, a number of approaches have been proposed to develop new potential therapeutics. Here we discuss some of the most promising ones: inhibition of tau phosphorylation, proteolysis and aggregation, promotion of intra- and extracellular tau clearance, and stabilization of microtubules. We also emphasize the need to achieve a full understanding of the biological roles and post-translational modifications of normal tau, as well as the molecular events responsible for selective neuronal vulnerability to tau pathology and its propagation. It is concluded that answering key questions on the relationship between Aβ and tau pathology should lead to a better understanding of the nature of secondary tauopathies, especially AD, and open new therapeutic targets and strategies.

KW - Alzheimer’s disease

KW - Amyloid β

KW - Microtubules

KW - Neurofibrillary degeneration

KW - Neuropathology

KW - Phosphorylation

KW - Protein aggregation

KW - Protein oligomerization

KW - Tau protein

KW - Tauopathies

UR - http://www.scopus.com/inward/record.url?scp=85006137585&partnerID=8YFLogxK

U2 - 10.3390/biom6010006

DO - 10.3390/biom6010006

M3 - Review article

VL - 6

JO - Biomolecules

JF - Biomolecules

SN - 2218-273X

IS - 1

M1 - 6

ER -